

# Ricolinostat

## Catalog No: tcsc0965



### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



### Specifications

**CAS No:**

1316214-52-4

**Formula:**

$C_{24}H_{27}N_5O_3$

**Pathway:**

Epigenetics;Cell Cycle/DNA Damage

**Target:**

HDAC;HDAC

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq$  50 mg/mL (115.34 mM)

**Alternative Names:**

ACY-1215;Rocilinostat

**Observed Molecular Weight:**

433.5


## Product Description

Ricolinostat (ACY-1215) is a potent and selective **HDAC6** inhibitor, with an **IC<sub>50</sub>** of 5 nM. ACY-1215 also inhibits **HDAC1**, **HDAC2**, and **HDAC3** with **IC<sub>50</sub>**s of 58, 48, and 51 nM, respectively.

IC50 & Target: IC50: 5 nM (HDAC6), 58 nM (HDAC1), 48 nM (HDAC2), 51 nM (HDAC3)<sup>[1]</sup>

***In Vitro:*** Ricolinostat (ACY-1215) has slight activity against HDAC8 (IC<sub>50</sub>=0.1 μM), and has minimal activity (IC<sub>50</sub>>1 μM) against HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, Sirtuin1, and Sirtuin2. The effect of Ricolinostat (ACY-1215) on multiple myeloma (MM) cell viability is determined with MTT assays using MM cell lines. Exposure of MM cell lines for 48 hours results in dose-dependent decreased viability, with IC<sub>50</sub> values ranging from 2-8μM. Ricolinostat (ACY-1215) demonstrates significant activity in the MM Bortezomib-resistant cell line (ANBL-6.BR), demonstrating the ability of Ricolinostat (ACY-1215) to overcome Bortezomib resistance<sup>[1]</sup>.

***In Vivo:*** Mice treated with Ricolinostat (ACY-1215), Bortezomib, or Ricolinostat plus Bortezomib show a significant delay in tumor growth (P=0.01, P=0.006, and P[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!